JP2019523630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523630A5 JP2019523630A5 JP2018555198A JP2018555198A JP2019523630A5 JP 2019523630 A5 JP2019523630 A5 JP 2019523630A5 JP 2018555198 A JP2018555198 A JP 2018555198A JP 2018555198 A JP2018555198 A JP 2018555198A JP 2019523630 A5 JP2019523630 A5 JP 2019523630A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 238000000375 direct analysis in real time Methods 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- -1 CO17-1A Proteins 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 201000007455 central nervous system cancer Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 235000013372 meat Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 108010055191 EphA3 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 101150047995 HCRTR1 gene Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 claims 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 102100035486 Nectin-4 Human genes 0.000 claims 1
- 101710043865 Nectin-4 Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 102100028141 Orexin/Hypocretin receptor type 1 Human genes 0.000 claims 1
- 108700036634 Orexin/Hypocretin receptor type 1 Proteins 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 102100036467 Protein delta homolog 1 Human genes 0.000 claims 1
- 101710119301 Protein delta homolog 1 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 102000050327 human TNFRSF9 Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004401 podocalyxin Human genes 0.000 claims 1
- 108090000917 podocalyxin Proteins 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021192091A JP2022058338A (ja) | 2016-04-22 | 2021-11-26 | Ｃｄ１３７に対する新規の二重特異性ポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1607046.8 | 2016-04-22 | ||
| GB201607046 | 2016-04-22 | ||
| PCT/EP2017/059656 WO2017182672A1 (en) | 2016-04-22 | 2017-04-24 | Novel bispecific polypeptides against cd137 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192091A Division JP2022058338A (ja) | 2016-04-22 | 2021-11-26 | Ｃｄ１３７に対する新規の二重特異性ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019523630A JP2019523630A (ja) | 2019-08-29 |
| JP2019523630A5 true JP2019523630A5 (cg-RX-API-DMAC7.html) | 2020-05-21 |
Family
ID=58609424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555198A Pending JP2019523630A (ja) | 2016-04-22 | 2017-04-24 | Ｃｄ１３７に対する新規の二重特異性ポリペプチド |
| JP2021192091A Pending JP2022058338A (ja) | 2016-04-22 | 2021-11-26 | Ｃｄ１３７に対する新規の二重特異性ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192091A Pending JP2022058338A (ja) | 2016-04-22 | 2021-11-26 | Ｃｄ１３７に対する新規の二重特異性ポリペプチド |
Country Status (14)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054526T2 (hu) | 2014-10-29 | 2021-09-28 | Bicyclerd Ltd | MT1-MMP-ra specifikus biciklusos peptid ligandumok |
| AU2017271601A1 (en) | 2016-05-27 | 2018-12-13 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| SI3472207T1 (sl) | 2016-06-20 | 2021-04-30 | F-Star Delta Limited | Vezavne molekule, ki vežejo PD-L1 in LAG-3 |
| RU2018142573A (ru) | 2016-06-20 | 2020-07-21 | Ф-Стар Бета Лимитед | Партнеры по связыванию lag-3 |
| MA45672A (fr) | 2016-07-14 | 2019-05-22 | Biontech Ag | Anticorps multispécifiques dirigés contre cd40 et cd137 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| AU2017332452B2 (en) * | 2016-09-23 | 2021-01-07 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| BR112019020940A2 (pt) | 2017-04-11 | 2020-05-05 | Inhibrx, Inc. | construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| WO2019016402A1 (en) * | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| EP3661948B1 (en) | 2017-08-04 | 2022-06-01 | BicycleTx Limited | Bicyclic peptide ligands specific for cd137 |
| KR20200083574A (ko) * | 2017-11-13 | 2020-07-08 | 크레센도 바이오로직스 리미티드 | Cd137 및 psma에 결합하는 분자 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CN111741976B (zh) | 2017-12-19 | 2024-09-17 | 英沃克斯制药有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
| CN109970865B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd137双向激活共刺激分子受体及其用途 |
| SG11202007678QA (en) | 2018-02-23 | 2020-09-29 | Bicycletx Ltd | Multimeric bicyclic peptide ligands |
| CR20250348A (es) | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-463) |
| JP7551500B2 (ja) * | 2018-04-04 | 2024-09-17 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| WO2019232323A1 (en) * | 2018-05-31 | 2019-12-05 | Board Of Regents, The University Of Texas System | Bi-specific antibodies and use thereof |
| WO2019234187A1 (en) * | 2018-06-06 | 2019-12-12 | Leadartis, S.L. | Trimeric polypeptide complexes and uses thereof |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| JP7596263B2 (ja) * | 2018-10-10 | 2024-12-09 | ザイムワークス ビーシー インコーポレイテッド | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 |
| CA3114693A1 (en) * | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| CN112638950B (zh) * | 2018-10-22 | 2024-09-06 | 南通壹宸生物医药科技有限公司 | 一种双特异性抗体 |
| BR112021010402A2 (pt) * | 2018-11-30 | 2021-08-24 | Abl Bio Inc. | Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| WO2020127374A2 (en) * | 2018-12-17 | 2020-06-25 | Alligator Bioscience Ab | Novel polypeptides |
| US20220073635A1 (en) * | 2018-12-17 | 2022-03-10 | Alligator Bioscience Ab | Novel polypeptides |
| GB201820556D0 (en) * | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| CN113195006A (zh) * | 2018-12-21 | 2021-07-30 | 锕医药有限责任公司 | 用于治疗癌症的放射免疫疗法和免疫检验点疗法的联合疗法 |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| GB201905100D0 (en) * | 2019-04-10 | 2019-05-22 | Antibody Innovation Ltd | Polypeptides and methods of use |
| CN113811541A (zh) | 2019-05-09 | 2021-12-17 | 拜斯科技术开发有限公司 | Ox40特异性的双环肽配体 |
| EP4004053A4 (en) * | 2019-07-26 | 2023-10-18 | ABL Bio, Inc. | BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND ITS USE |
| US12240913B2 (en) * | 2019-07-26 | 2025-03-04 | Abl Bio Inc. | Anti-HER2/anti-4-1BB bispecific antibody and use thereof |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| HUE072242T2 (hu) * | 2019-10-03 | 2025-11-28 | Bicycletx Ltd | Heterotandem biciklusos peptidkomplexek |
| EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| WO2021101346A1 (en) * | 2019-11-21 | 2021-05-27 | Dong-A St Co., Ltd. | Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof |
| US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| CA3161733A1 (en) | 2020-01-07 | 2021-05-15 | Everett Stone | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CN115190889A (zh) * | 2020-02-28 | 2022-10-14 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
| CN115151573A (zh) * | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
| US20230265202A1 (en) * | 2020-04-15 | 2023-08-24 | Zymeworks Inc. | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
| CN116249555A (zh) | 2020-05-19 | 2023-06-09 | 勃林格殷格翰国际有限公司 | 用于癌症治疗的结合分子 |
| CA3183462A1 (en) * | 2020-06-30 | 2022-01-06 | Lei Shi | 4-1bb-binding protein and use thereof |
| KR20230042524A (ko) | 2020-08-07 | 2023-03-28 | 주식회사 유틸렉스 | 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도 |
| CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
| US20240084025A1 (en) * | 2021-01-25 | 2024-03-14 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| EP4396235A4 (en) * | 2021-09-02 | 2025-07-02 | Memorial Sloan Kettering Cancer Center | ANTI-CD33 ANTIBODIES AND THEIR USES |
| US20240417482A1 (en) * | 2021-10-12 | 2024-12-19 | Concept To Medicine Biotech Co., Ltd. | Single-domain 4-1bb antibodies |
| WO2023174521A1 (en) * | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4584300A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Multispecific constructs and uses thereof |
| CN119790076A (zh) * | 2022-09-22 | 2025-04-08 | 成都盛世君联生物技术有限公司 | 一种抗4-1bb纳米抗体及其制备和应用 |
| EP4606384A1 (en) * | 2022-10-19 | 2025-08-27 | Astellas Pharma, Inc. | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment |
| WO2024117781A1 (ko) * | 2022-11-29 | 2024-06-06 | (주) 테라베스트 | Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도 |
| WO2024143643A1 (ko) * | 2022-12-30 | 2024-07-04 | 앱클론(주) | Cd137에 특이적으로 결합하는 어피바디 및 이의 용도 |
| WO2025035107A2 (en) * | 2023-08-09 | 2025-02-13 | Curadh Mtr, Inc. | Trophoblast glycoprotein antibody compositions and methods of use |
| WO2025056180A1 (en) * | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| KR20020049054A (ko) * | 1999-11-18 | 2002-06-24 | 찰스 굿맨 | 항체 |
| US7172759B2 (en) * | 2000-02-01 | 2007-02-06 | Pangenetics Bv | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| WO2006031653A2 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20130295091A1 (en) | 2011-01-10 | 2013-11-07 | University Of Zurich | Combination therapy including tumor associated antigen binding antibodies |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| MX356947B (es) | 2011-08-23 | 2018-06-20 | Roche Glycart Ag | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. |
| MX2014003313A (es) * | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Moleculas de union biespecificas para 5t4 y cd3. |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| KR102568808B1 (ko) * | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
| US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| CN112546231A (zh) * | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| SI3623386T1 (sl) * | 2015-01-08 | 2022-09-30 | BioNTech SE | Agonistična TNF receptor vezavna sredstva |
| EP3245227A4 (en) * | 2015-01-14 | 2018-07-25 | Compass Therapeutics LLC | Multispecific immunomodulatory antigen-binding constructs |
| US11008396B2 (en) * | 2015-05-21 | 2021-05-18 | Alligator Bioscience Ab | Polypeptides |
| CA3053803A1 (en) * | 2017-02-24 | 2018-08-30 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| WO2019016402A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
-
2017
- 2017-04-24 ES ES17718928T patent/ES2910365T3/es active Active
- 2017-04-24 US US16/094,127 patent/US20190169308A1/en not_active Abandoned
- 2017-04-24 JP JP2018555198A patent/JP2019523630A/ja active Pending
- 2017-04-24 KR KR1020187030680A patent/KR102426765B1/ko active Active
- 2017-04-24 AU AU2017252233A patent/AU2017252233A1/en not_active Abandoned
- 2017-04-24 MX MX2018012897A patent/MX2018012897A/es unknown
- 2017-04-24 DK DK17718928.9T patent/DK3445788T3/da active
- 2017-04-24 RU RU2018139339A patent/RU2018139339A/ru unknown
- 2017-04-24 BR BR112018071612-0A patent/BR112018071612A2/pt not_active IP Right Cessation
- 2017-04-24 CA CA3021618A patent/CA3021618A1/en active Pending
- 2017-04-24 WO PCT/EP2017/059656 patent/WO2017182672A1/en not_active Ceased
- 2017-04-24 CN CN201780025116.2A patent/CN109195994A/zh active Pending
- 2017-04-24 EP EP17718928.9A patent/EP3445788B1/en active Active
-
2018
- 2018-10-21 IL IL262482A patent/IL262482A/en unknown
-
2021
- 2021-09-23 US US17/482,708 patent/US12173082B2/en active Active
- 2021-11-26 JP JP2021192091A patent/JP2022058338A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523630A5 (cg-RX-API-DMAC7.html) | ||
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| Bathula et al. | Nanobodies: the future of antibody-based immune therapeutics | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| US20200362047A1 (en) | Single domain antibodies that bind to cd137 | |
| CN118546960A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| WO2021035188A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| CN116589582A (zh) | 抗cd24组合物及其用途 | |
| JP2018502050A5 (cg-RX-API-DMAC7.html) | ||
| EP4257610A1 (en) | Ror1-targeting antibody and use thereof | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| WO2022222910A1 (zh) | 靶向gprc5d的抗体及其用途 | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| CA3068045A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
| TW202030206A (zh) | 新型雙特異性cd3/cd20多肽複合物 | |
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| US20210284730A1 (en) | Materials and methods for modulating delta chain mediated immunity | |
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| WO2022095801A1 (zh) | 靶向lir1的抗体及其用途 | |
| CA3194771A1 (en) | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer | |
| CN114539402A (zh) | 靶向Claudin18.2的抗体及其用途 | |
| JPWO2020092467A5 (cg-RX-API-DMAC7.html) |